Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Authors
Keywords
-
Journal
JOURNAL OF HEADACHE AND PAIN
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-03
DOI
10.1186/s10194-021-01247-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
- (2021) Michael Ament et al. JOURNAL OF HEADACHE AND PAIN
- Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
- (2021) Todd J. Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura
- (2020) Claudia Altamura et al. CEPHALALGIA
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
- (2020) Fabrizio Vernieri et al. NEUROLOGICAL SCIENCES
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Identifying and managing refractory migraine: barriers and opportunities?
- (2019) Linda D’Antona et al. JOURNAL OF HEADACHE AND PAIN
- Content Validity of HIT‐6 as a Measure of Headache Impact in People With Migraine: A Narrative Review
- (2019) Carrie R. Houts et al. HEADACHE
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice
- (2018) HEADACHE
- Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
- (2018) Stefanie Förderreuther et al. JOURNAL OF HEADACHE AND PAIN
- Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2018) Lars Jacob Stovner et al. LANCET NEUROLOGY
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
- (2016) Zsolt Hepp et al. CEPHALALGIA
- The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients
- (2016) P Barbanti et al. CEPHALALGIA
- The pharmacogenomics of epilepsy
- (2015) Valentina Franco et al. Expert Review of Neurotherapeutics
- Migraine and body mass index categories: a systematic review and meta-analysis of observational studies
- (2015) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- The pharmacogenomics of epilepsy
- (2015) Valentina Franco et al. Expert Review of Neurotherapeutics
- Placebo and other psychological interactions in headache treatment
- (2012) A. Autret et al. JOURNAL OF HEADACHE AND PAIN
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1
- (2012) S.D. Silberstein et al. NEUROLOGY
- Calcitonin gene-related peptide: A molecular link between obesity and migraine?
- (2010) A. Recober et al. DRUG NEWS & PERSPECTIVES
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
- (2010) David W. Dodick et al. HEADACHE
- EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force
- (2009) S. Evers et al. EUROPEAN JOURNAL OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started